NCT06723964View on ClinicalTrials.gov

A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

November 30, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

AP505

AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.

Trial Locations (1)

Unknown

AP Biosciences, Inc., Taipei

Sponsors
All Listed Sponsors
lead

AP Biosciences Inc.

INDUSTRY

NCT06723964 - A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors | Biotech Hunter | Biotech Hunter